The crying in the car park after a perfectly ordinary Tuesday was what finally sent me looking for answers. Nothing bad had happened. Nothing at all. That 'nothing' was the clue — because real grief has a reason, and this didn't. When it turned out my brain's entire emotional dampening system was being dismantled by falling oestrogen, the relief of having a name for it was enormous. You are not falling apart. Your brain is in transition.
Learn more about Rose →Oestrogen receptors are densely concentrated in the prefrontal cortex — the region responsible for moderating emotional responses and keeping reactions proportionate to events. As oestrogen levels fluctuate and decline in perimenopause, this top-down regulatory system becomes less efficient, meaning the brain's emotional brake pedal loses pressure. The result is that feelings that would normally be filtered or dampened before reaching full expression break through more easily and more intensely.
The amygdala is the brain's threat-detection and emotional-amplification hub, and oestrogen plays a key role in keeping its reactivity calibrated. When oestrogen drops, the amygdala effectively becomes more trigger-happy — firing stronger emotional signals in response to stimuli that would previously have passed without much notice. Neuroimaging studies have shown increased amygdala reactivity in women during low-oestrogen phases of their cycle, which scales up significantly during perimenopausal fluctuation.
Oestrogen stimulates the production of serotonin and increases the sensitivity of serotonin receptors across the brain, including in regions governing mood stability and emotional resilience. As oestrogen becomes erratic and then lower in perimenopause, serotonin availability decreases — reducing the neurochemical cushioning that helps regulate tearfulness and emotional steadiness. This is one of the reasons SSRIs, which target the serotonin system, are sometimes used off-label to manage perimenopausal mood symptoms.
Progesterone metabolises in the brain into a neurosteroid called allopregnanolone, which acts on GABA receptors — the same receptors targeted by anti-anxiety medications — to produce a calming, stabilising effect on the nervous system. In perimenopause, progesterone levels often drop before oestrogen does and become increasingly irregular, meaning this built-in neurological tranquilliser becomes unpredictable and then scarce. Women frequently describe a new, free-floating emotional volatility that corresponds precisely with this progesterone withdrawal.
Oestrogen modulates the hypothalamic-pituitary-adrenal (HPA) axis — the command chain that governs cortisol release and the stress response. Without adequate oestrogen, the HPA axis becomes less well-regulated, making the stress response more easily triggered and slower to switch off. This means perimenopausal women are neurologically primed to reach the point of overwhelm faster and recover from it more slowly, which manifests physically as tears.
Oestrogen supports dopaminergic activity in the brain, particularly in circuits involved in motivation, pleasure, and emotional resilience. When oestrogen fluctuates, dopamine signalling becomes less consistent, contributing to a lowered emotional baseline — sometimes described as a kind of grey flatness punctuated by sudden emotional surges. This neurological state makes the brain less able to buffer ordinary disappointments or frustrations, so they register and overflow as tears rather than being processed and released quietly.
Poor sleep — itself a hallmark perimenopausal symptom driven by night sweats and oestrogen's role in sleep architecture — significantly impairs the prefrontal cortex's ability to regulate amygdala activity. Research has shown that even one night of disrupted sleep increases amygdala reactivity by up to 60%, and perimenopausal women often endure months or years of fragmented sleep. This means the neurological vulnerabilities created by hormone change are continuously reinforced by the sleep disruption those same hormonal changes cause.
The neurobiological signature of low oestrogen — reduced serotonin, disrupted dopamine, impaired HPA regulation, and heightened amygdala sensitivity — overlaps substantially with what is observed in clinical depression. This does not mean perimenopausal tearfulness is depression, but it explains why the emotional experience can feel indistinguishable from it and why it is so often misdiagnosed. Recognising it as a hormone-driven neurological state rather than a psychological disorder changes both the framing and the appropriate treatment pathway.
It is a common misconception that symptoms are worst when oestrogen is at its lowest; in reality, the unpredictable swings characteristic of perimenopause are neurologically more disruptive than a sustained low level. The brain adapts over time to lower hormone baselines, but it cannot adapt quickly to levels that spike and crash irregularly — and this volatility is precisely what defines the perimenopausal transition. This is why many women find their emotional dysregulation most severe in early-to-mid perimenopause, when fluctuations are at their most chaotic, rather than in the years immediately after their final period.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.